NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment - Scoping

Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

COPD is more common in men and people over 40. At consultation, stakeholders noted disparities in care for patients with COPD linked to ethnicity, age and socioeconomic status. Stakeholders commented that COPD disproportionately affects people from lower socioeconomic backgrounds, that there is unequal access to diagnostic tests and maintenance treatments and that younger people are frequently underdiagnosed which could result in delays for certain populations accessing dupilumab. COPD patients are less mobile and often unable to access care, as evidenced by the disparity in pulmonary rehab.

They noted that it is important for committee to consider the disproportionate impact of COPD on these disadvantaged groups and how the provision of a targeted, effective, and well-tolerated treatment could improve their health and reduce inequalities.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider health inequality evidence submitted during the course of the appraisal. It should also consider whether a draft recommendation would make it harder for anyone to access dupilumab.

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of dupilumab for treating moderate to severe chronic obstructive pulmonary disease

1 of 2

Has any change to the draft scope been agreed to highlight potential equality issues?

No – See above

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name):Janet Robertson.....

Date: 23 August 2024

2 of 2